Contract drug developer AMRI is expanding its platform to include protein R&D, investing in a market the company expects to boom over the coming years.
Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.
Contract developer AMRI has closed its $110 million acquisition of drug manufacturer Oso Biopharmaceuticals, its second deal this year and one the company believes will help pad its annual revenue.
AMRI is building up its contract manufacturing operations and has completed a $110 million deal for Oso Biopharmaceuticals Manufacturing to add that company's expertise in complex injectable drug products to its stable.
AMRI said the Albuquerque, NM-based Oso will expand its capabilities in small-molecule and biologics manufacturing.
In the midst of an ongoing reorganization, contract developer AMRI has made another buy in manufacturing, signing a deal to scoop up CMO OsoBio for $110 million in cash.
Contract drug developer AMRI turned in a stagnant revenue quarter, watching profits slip as it prepares to shake off its dependence on royalties and embrace a future in large-scale manufacturing.
Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.
AMRI has wrapped up its $41 million effort to acquire contract manufacturer Cedarburg Pharmaceuticals, and the company says it's in line for an immediate windfall.
AMRI saw a big jump in revenues last year as its manufacturing side kicked in additional revenue. Now it wants some more of that action and so is picking up Cedarburg Pharmaceuticals, a specialist in APIs for controlled drugs, in a $41 million deal.